» Articles » PMID: 36135072

Outcome of Reoperation for Local Recurrence Following En Bloc Resection for Bone Giant Cell Tumor of the Extremity

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2022 Sep 22
PMID 36135072
Authors
Affiliations
Soon will be listed here.
Abstract

En bloc resection is typically performed to treat giant cell tumors of bone (GCTB), particularly when curettage can be challenging owing to extensive bone cortex destruction with soft tissue extension. Few reports have addressed the clinical outcomes after reoperation for local recurrence in patients with GCTB who underwent en bloc resection. In this multicenter retrospective study, we investigated local recurrence, distant metastasis, malignant transformation, mortality, and limb function in patients treated for local recurrence following en bloc resection for GCTB. Among 205 patients who underwent en bloc resection for GCTB of the extremities between 1980 and 2021, we included 29 with local recurrence. En bloc resection was performed for large tumors with soft tissue extension, pathological fractures with joint invasion, complex fractures, and dispensable bones, such as the proximal fibula and distal ulna. Local re-recurrence, distant metastasis, malignant transformation, and mortality rates were 41.4% (12/29), 34.5% (10/29), 6.9% (2/29), and 6.9% (2/29), respectively. The median Musculoskeletal Tumor Society score was 26 (interquartile range, 23-28). The median follow-up period after surgery for local recurrence was 70.1 months (interquartile range, 40.5-123.8 months). Local recurrence following en bloc resection for GCTB could indicate an aggressive GCTB, necessitating careful follow-up.

Citing Articles

Denosumab combined with en bloc resection and arthrodesis for recurrent grade 3 giant cell tumor of bone in distal radius.

Li Z, Deng Z, Yang Y, Gao D, Zhang Q, Niu X J Orthop Surg Res. 2024; 19(1):607.

PMID: 39342379 PMC: 11437736. DOI: 10.1186/s13018-024-05092-1.


Giant cell tumor of bone at distal radius suffered more soft tissue recurrence and ultrasonography is effective to detect the soft tissue recurrence.

Cui L, Sun Y, Jin T, Fan D, Liu W Discov Oncol. 2024; 15(1):103.

PMID: 38573423 PMC: 10994907. DOI: 10.1007/s12672-024-00918-0.


Treatment of Recurrent Giant Cell Tumor of Bones: A Systematic Review.

Pitsilos C, Givissis P, Papadopoulos P, Chalidis B Cancers (Basel). 2023; 15(13).

PMID: 37444396 PMC: 10340062. DOI: 10.3390/cancers15133287.


Images of giant cell tumor and chondroblastoma around the knee: retrospective analysis of 99 cases.

Ma J, Wu Y, Wen J, Zhong Z, Yu B, Liu C Quant Imaging Med Surg. 2023; 13(2):787-800.

PMID: 36819259 PMC: 9929425. DOI: 10.21037/qims-22-616.


Custom-Made 3D-Printed Prosthesis after Resection of a Voluminous Giant Cell Tumour Recurrence in Pelvis.

Khal A, Apostu D, Schiau C, Bejinariu N, Pesenti S, Jouve J Diagnostics (Basel). 2023; 13(3).

PMID: 36766590 PMC: 9914636. DOI: 10.3390/diagnostics13030485.

References
1.
Takeuchi A, Tsuchiya H, Niu X, Ueda T, Jeon D, Wang E . The prognostic factors of recurrent GCT: a cooperative study by the Eastern Asian Musculoskeletal Oncology Group. J Orthop Sci. 2011; 16(2):196-202. DOI: 10.1007/s00776-011-0030-x. View

2.
Goldring S, Roelke M, Petrison K, Bhan A . Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest. 1987; 79(2):483-91. PMC: 424109. DOI: 10.1172/JCI112838. View

3.
Gupta R, Seethalakshmi V, Jambhekar N, Prabhudesai S, Merchant N, Puri A . Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann Diagn Pathol. 2008; 12(4):239-248. DOI: 10.1016/j.anndiagpath.2007.09.002. View

4.
Joo M, Lee Y, Park H, Chung Y, Yoon C . Secondary Malignancy in Giant Cell Tumor: A Single-Center Study. Curr Oncol. 2022; 29(6):4068-4080. PMC: 9221612. DOI: 10.3390/curroncol29060324. View

5.
Rock M, Pritchard D, Unni K . Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am. 1984; 66(2):269-74. View